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Chronic kidney disease (CKD) accelerates muscle protein
degradation by stimulating the ubiquitin proteasome system
through activation of the E3 ligases, Atrogin-1/MAFbx and
MuRF-1. Forkhead transcription factors (FoxOs) can control
the expression of these E3 ligases, but the contribution of
individual FoxOs to muscle wasting is unclear. To study this
we created mice with a muscle-specific FoxO1 deletion. The
absence of FoxO1 blocked 70% of the increase in E3 ligase
induction by CKD as well as the proteolysis and loss of
muscle mass. Thus, FoxO1 has a role in controlling ubiquitin
proteasome system-related proteolysis. As microRNA (miR)-
486 reportedly dampens FoxO1 expression and its activity,
we transfected a miR-486 mimic into primary cultures of
myotubes and found this blocked dexamethasone-stimulated
protein degradation without influencing protein synthesis.
It also decreased FoxO1 protein translation and increased
FoxO1 phosphorylation by downregulation of PTEN
phosphatase, a negative regulator of p-Akt. To test its
efficacy in vivo, we electroporated miR-486 into muscles and
found that the expression of the E3 ligases was suppressed
and muscle mass increased despite CKD. Thus, FoxO1 is a
dominant mediator of CKD-induced muscle wasting, and
miR-486 coordinately decreases FoxO1 and PTEN to protect
against this catabolic response.
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It has been known for decades that chronic kidney disease
(CKD) and its complications (for example, metabolic acidosis,
excess glucocorticoid production, and angiotensin II or
impaired insulin/insulin-like growth factor 1 (IGF-1) signal-
ing) stimulate the loss of muscle protein. Understanding the
mechanisms for muscle wasting is needed to design treatments
as it is associated with increased morbidity and mortality. One
mechanism involves activation of caspase-3 that can cleave
the complex structure of the muscle to produce substrates for
the ubiquitin–proteasome system (UPS).1–3 Caspase-3 also
increases the proteolytic activity of the proteasome.4 Regarding
mechanisms, there is evidence that a common group of
biochemical and transcriptional adaptations in muscle cells
stimulate muscle wasting in different conditions.5,6 For
example, increased expression of E3 ubiquitin ligases,
Atrogin-1/MAFbx and MuRF-1, act to accelerate muscle
protein degradation via the UPS.7,8 Stimuli that increase the
expression of Atrogin-1/MAFbx and MuRF-1 include changes
in phosphatidylinositol 3-kinase (PI3K)/Akt/FoxO signaling
because a reduced activity of PI3K (for example, insulin
resistance) will decrease the phosphorylation of Akt and its
downstream effectors, such as forkhead transcription factors
(FoxOs). Dephosphorylated FoxOs can enter the nucleus to
promote the expression of Atrogin-1/MAFbx and MuRF-1,
increasing in muscle proteolytic activity via the UPS.2,9,10
Insulin and IGF-1 signaling affect muscle protein metabolism
by changing insulin receptor substrates and/or isoforms of
Akt (Akt1, Akt2, and Akt3) plus differences in FoxOs.
In skeletal muscles, there are three FoxO transcription
factors, FoxO1, FoxO3a, and FoxO4, and in a murine model
of starvation or disuse-induced muscle atrophy, FoxO3a was
found to upregulate Atrogin-1/MAFbx.10,11 In contrast, in a
model of high dose of dexamethasone (Dex) or sepsis-
induced muscle wasting, FoxO1 was shown to mediate
Atrogin-1/MAFbx and MuRF-1 transcription.9,12 In another
report, FoxO4 was linked to tumor necrosis factor-a-induced
expression of Atrogin-1/MAFbx in C2C12 myotubes.13 These
data indicate that different members of the FoxO family
respond to various catabolic conditions by promoting
Atrogin-1/MAFbx and MuRF-1 expression.
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The recent discoveries of the mechanisms mediated by small
microRNAs (miRNAs) suggest a potential means of interfering
with muscle catabolism. The miRNAs act by targeting sequences
in the 30-untranslated region of mRNAs to inhibit translation or
to increase the degradation of mRNA, limiting the expression
of specific proteins. However, the responses to miRNAs are
complex, because individual miRNAs can target several mRNAs,
whereas an individual mRNA can be targeted by more than one
miRNA. This diversity might explain why an individual protein
is not routinely inhibited in response to a miRNA.14 Second,
miRNAs are expressed in a tissue-specific manner,15 and in the
muscles, the expression profiles of miRNAs can change
dramatically in diseases affecting the muscles.16–18 For example,
miR-1 and miR-206 are induced during differentiation of
satellite cells or primary myoblasts, whereas miR-29 was found
to regulate the translation of the Ying-Yang protein, improving
muscle cell proliferation.19,20 Our interest in miRNAs was
stimulated by the report that miR-486 can modulate PI3K/Akt
signaling in cardiomyocytes by targeting the phosphatase and
tensin homolog (PTEN) and FoxO1. In that report, changes in
protein metabolism were not evaluated.21 We have examined
how miR-486 influences muscle metabolism because FoxO1
and PTEN activities might affect muscle protein turnover.2,22
Specifically, we studied whether muscle-specific deletion of
FoxO1 would blunt CKD-induced muscle wasting. A role of
FoxO1 was confirmed, and hence we examined if miR-486
could improve muscle mass in mice with CKD.
RESULTS
Muscle-specific FoxO1 knockout (MFKO) protects against
CKD-induced muscle wasting
To examine the relationship between FoxO1 and Atrogin-1/
MuRF-1 expression, we generated mice with muscle-specific
knockout of FoxO1 (MFKO). These mice grow normally and
their muscles exhibit a normal distribution of myofiber sizes
(Figure 1a and d). Using western blots and immunostaining,
we confirmed that FoxO1 is absent in myofibers from MFKO
mice (Figure 1a). Importantly, deletion of FoxO1 did not
alter the expression of FoxO3a or FoxO4 (Figure 1b), and
when CKD was induced in MFKO mice, there was no
significant loss of muscle mass in tibialis anterior (TA),
extensor digitorum longus (EDL), or soleus (Sol) muscles. In
contrast, CKD did decrease the weights of muscles from lox/
lox control mice (Figure 1c). These changes were confirmed
by an analysis of cross-sectional areas of myofibers in TA
muscles (Figure 1e).
To explore why CKD did not induce muscle atrophy in
MFKO mice, we measured the protein synthesis and
degradation rates of EDL and Sol muscles. CKD did not
significantly suppress protein synthesis in the muscles from
lox/lox or MFKO mice when compared with the values in the
muscles of the respective control mice (Figure 2a). In contrast,
CKD stimulated protein degradation in the muscles of lox/lox
mice but not in the muscles of MFKO mice (Figure 2b). In TA
and Sol muscles of lox/lox mice, CKD also induced the
expression of Atrogin-1/MAFbx and MuRF-1 (Figure 2c and
Supplementary Figure S1B online). As with protein degrada-
tion, the expression of these E3 ligases was suppressed in mice
with MFKO. Importantly, these responses occurred even
though the muscle levels of p-Akt or the presence of FoxO3a
and FoxO4 did not change (Figure 2d).
In another model of muscle catabolism, we treated MFKO
mice with a pharmacologic dose of Dex (5 mg/kg/day).23
After 2 weeks, the distribution of myofiber sizes in TA
muscles of lox/lox mice were shifted to the left. This response
was largely blocked in the muscles of MFKO mice
(Supplementary Figure S2A online). In the muscles of lox/
lox mice, Dex elicited the expected increase in Atrogin-1/
MAFbx and MuRF-1 mRNAs. These catabolic responses were
largely suppressed in the muscles of MFKO mice (Supple-
mentary Figure S2B online). Thus, FoxO1 is a dominant
transcription factor acting to stimulate muscle atrophy in
at least two catabolic conditions (CKD or high dose of
glucocorticoid administration).
The influence of miR-486 on protein synthesis and
degradation in muscle cells
Because PTEN2 and FoxO1 (Figure 1) influence muscle
protein wasting, we hypothesized that enhancing miR-486 in
the muscles might improve muscle protein turnover. To
examine this hypothesis, we first introduced a miR-486
‘mimic’ into primary cultures of mouse skeletal muscle cells
and measured the rates of protein synthesis and degradation.
In transfected primary culture of myotubes, the miR-486
mimic increased 412-fold compared with cells transfected
with control miRNA (Figure 3a). Following treatment with
Dex, the miR-486 mimic significantly dampened proteolysis
(Figure 3b). Dex also suppressed protein synthesis in cultured
myotubes, and transfection of these cells with miR-486
mimic tended to counteract this response (Figure 3c). These
results demonstrate that enhancing miR-486 can suppress
Dex-stimulated muscle protein degradation.
MiR-486 suppresses glucocorticoid-induced expression of
Atrogin-1/MAFbx and MuRF-1
As the E3 ubiquitin ligases, Atrogin-1/MAFbx and MuRF-1,
are intimately involved in the UPS-mediated muscle
proteolysis, we examined whether enhancing miR-486 in
muscle cells would suppress expression of these E3 ubiquitin
ligases. In primary cultures of muscle cells, Dex produced the
expected increase in Atrogin-1/MAFbx and MuRF-1 mRNAs
in myotubes. The increase in these E3 ubiquitin ligases was
suppressed by the miR-486 mimic (Figure 4a). Similarly,
introduction of the miR-486 mimic blocked the suppression
of Akt phosphorylation induced by Dex (Figure 4b). Because
miR-486 can target the 30-untranslated region of PTEN,22 we
measured the PTEN protein in myotubes. The miR-486
mimic significantly decreased the level of PTEN protein
(Figure 4c). A decrease in PTEN induced by the miR-486
mimic would raise p-Akt by inhibiting PTEN expression, and
this response in turn would be a mechanism that suppresses
Atrogin-1/MAFbx expression.
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The downstream target of p-Akt, FoxO1 has been shown
to influence MuRF-1 transcription by binding to MuRF-1
promoter or acting synergistically with the glucocorticoid
receptor.24 We found that Dex not only decreased the levels
of p-FoxO1, but also upregulated FoxO1 in muscle cells;
transfection with the miR-486 mimic reversed these
responses (Figure 4d). The results confirm that FoxO1 and
PTEN are targets of miR-486 in skeletal muscle cells. They
also demonstrate that miR-486 can suppress both Atrogin-1/
MAFbx and MuRF-1 expression by repressing FoxO1.
Enhancing miR-486 protects against CKD-induced loss of
skeletal muscle
We examined if CKD influences miR-486 expression in the
muscles and found significant decrease in miR-486 in the
muscles of CKD mice (Supplementary Figure S3A online).
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Figure 1 |Muscle-specific FoxO1 knockout (MFKO) prevents chronic kidney disease (CKD)-induced muscle atrophy. (a) FoxO1 protein
is absent in myofibers of MFKO mice as assessed by immunostaining. (b) Western blot of muscles from MFKO mice revealed that FoxO1 was
markedly decreased, whereas FoxO3a and FoxO4 levels were unchanged. (c) Muscle mass was evaluated by muscle weight normalized to
tibia bone length; MFKO prevented the loss of weight of tibialis anterior (TA), extensor digitorum longus (EDL), and soleus (Sol) muscles in
CKD mice (*Po0.05 vs. lox/lox þCKD, n¼ 5). (d) The distribution of muscle fiber sizes in control (lox/lox) or MFKO mice was identical (n¼ 3,
4200 myofibers in each mouse were examined). (e) The leftward shift of muscle fiber sizes in lox/lox mice with CKD was prevented in MFKO
mice with CKD (n¼ 5, 4200 myofibers in each mouse were examined).
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Because our in vitro experiments showed that miR-486
suppresses muscle protein degradation by enhancing PI3K/
Akt signaling, we hypothesized that enhancing miR-486
might block muscle wasting in CKD mice. To test this
possibility, we transfected either the miR-486 mimic or a
control miRNA into the TA muscles of normal and CKD
mice using electroporation. First, we validated this process by
electroporating Dy547-labeled Caenorhabditis elegans miRNA
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Figure 2 |Proteolysis and ubiquitin E3 ligases were largely blocked in the muscles of MFKO (muscle-specific FoxO1 knockout) mice
with chronic kidney disease (CKD). (a) The absence of FoxO1 minimally influenced the rates of protein synthesis in extensor digitorum
longus (EDL) and soleus (Sol) muscles (n¼ 5). (b) Rates of protein degradation in EDL and Sol muscles of MFKO and lox/lox mice indicated
that deletion of FoxO1 suppressed the increase in muscle proteolysis stimulated by CKD (n¼ 5). (c) The expression of Atrogin-1/MAFbx and
MuRF-1 mRNAs in tibialis anterior (TA) muscles was accessed by northern blotting. The increased expression of Atrogin-1/MAFbx and MuRF-
1 in the muscles of CKD, lox/lox mice were eliminated in the muscles of MFKO mice with CKD (*Po0.01 vs. lox/loxþCKD, n¼ 5). GAPDH,
glyceraldehyde-3-phosphate dehydrogenase. (d) Phosphorylation of Akt and FoxO transcription factors were examined by western blotting.
CKD suppressed the p-Akt (Ser 473) and p-FoxO1 (Thr 24) and FoxO3a (Thr 32), but did not change the p-FoxO4 (Ser 262) in the muscles of
lox/lox and MFKO mice.
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(a control miRNA) into TA muscles and examined the
fluorescence intensity in muscle fibers. As shown in Figure 5,
few of the myofibers exhibited fluorescence without electro-
poration. With electroporation, however, the fluorescence of
Dy547-labeled control miRNA was present in 470% of
myofibers, and the expression of this control miRNA lasted
for at least 3 weeks as assessed by real-time PCR (Figure 5f,
bar graph). We also detected a 410-fold increase in miR-486
in TA muscles at 2 weeks after electroporation of the
miR-486 mimic (Figure 6a). As with the control miRNA,
the miR-486 mimic was detected in 470% of myofibers by
in situ hybridization (Figure 6b and Supplementary Figure S3B
online). Importantly, muscle mass (assessed as the ratio of TA
muscle weight to tibia bone length) in CKD mice was sig-
nificantly increased when muscles were electroporated with
the miR-486 mimic (Figure 6c). This result was confirmed by
finding a rightward shift in the distribution of the cross-
sectional areas of myofibers when compared with results in
muscles electroporated with the control miRNA (Figure 6d).
The miR-486 decreases FoxO1 protein and promotes FoxO1
phosphorylation to suppress E3 ubiquitin ligases
The expression of both Atrogin-1/MAFbx and MuRF-1 also
decreased in muscles electroporated with the miR-486 mimic
(Figure 7a). To assess how it might be related to PI3K/Akt
signaling in the skeletal muscle, we examined FoxO1 and
PTEN proteins in TA muscles electroporated with the miR-
486 mimic. There was a decrease in both FoxO1 and PTEN
proteins compared with results in muscles treated with
control miRNA (Figure 7b and c). This was accompanied by
phosphorylation of Akt at the serine 473 site plus the
expected increase in phosphorylation of FoxO1 (Figure 7c
and d). We also analyzed the expression of miR-1, miR-133,
miR-29, and miR-206 because these muscle-enriched miR-
NAs are reported to affect skeletal muscle growth.20,25
Expression of these miRNAs did not significantly change
when the miR-486 mimic was electroporated into the muscle
compared with results obtained in TA muscles electroporated
with control miRNA (Figure 7e). Thus, the improvement in
muscle mass in CKD mice following treatment with miR-486
mimic was mainly due to an enhanced level of miR-486.
DISCUSSION
Much has been learned about the pathophysiology of skeletal
muscle wasting in catabolic conditions, but fewer strategies
have been uncovered that block loss of muscle mass. We
tested whether increasing the expression of a specific miRNA,
miR-486, would benefit muscle metabolism by blocking a
catabolic mediator, FoxO1. In two models of muscle wasting,
CKD or administration of a high dose of glucocorticoids,
miR-486 suppressed protein degradation in the muscle,
improving muscle mass by increasing Akt signaling and
repressing FoxO1, ubiquitin E3 ligases (Figure 8).
FoxO1, FoxO3a, or FoxO4 can initiate the transcription of
the E3 ubiquitin ligases, Atrogin-1/MAFBx and MuRF-1, the
enzymes responsible for the specificity of muscle protein
degradation by the UPS.5 To determine which FoxO is the
important mediator of CKD-induced muscle wasting in the
condition we studied, we initially investigated mice with
muscle-specific knockout of FoxO1 (that is, MFKO mice). In
the MFKO mice, there was no change in FoxO3a or FoxO4
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Figure 3 |MicroRNA (miR)-486 blocked dexamethasone (Dex)-
stimulated protein degradation in myotubes. (a) The miR-486
mimic (miR-486mc) was transfected into a primary culture of
myotubes and the efficiency of transfection was assessed with
real-time quantitative PCR. The miR-486 mimic increased
412-fold compared with results in cells transfected with control
miRNA (CTL-miR). (b) The miR-486 mimic suppressed muscle
proteolysis stimulated by Dex. Primary culture of myotubes
(transfected with miR-486mimic or CTL-miR) was incubated with
[3H]-tyrosine overnight and then treated with phosphate-buffered
saline (PBS) or 2 mm Dex. The released radioactivity (indicating
proteins degraded) was plotted as a percentage of total
[3H]-tyrosine incorporated into cell proteins. The rates of
proteolysis (calculated from the linear slopes between 16 and
24 h) are shown. Measurements were done in duplicate and
independently repeated three times (*Po0.05 vs. CTL-miRþDex).
(c) miR-486 mimic exerted minimal changes in protein synthesis in
primary culture of myotubes. Protein synthesis was measured as
the incorporation of [3H]-tyrosine after treatment with or without
Dex (2 mmol/l). Measurements were done in duplicate and
independently repeated three times. NS, not significant.
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expression in muscle (Figure 1). Second, the transcriptions of
Atrogin-1/MAFbx and MuRF-1 were reduced 470% in the
muscles of MFKO mice with CKD. Third, with a decrease in
these E3 ubiquitin ligases, CKD-induced muscle proteolysis
was blocked in MFKO mice. This conclusion was supported
when we assessed the cross-sectional areas of muscle fiber
sizes in MFKO mice (Figure 2). Thus, our results reveal that
FoxO1 is a dominant mediator of CKD-induced muscle
wasting. Its deletion suppresses muscle protein wasting by a
mechanism that involves blocking the expression of Atrogin-
1/MAFbx and MuRF-1. To document the prominent role of
FoxO1, we extended the experiments and found that miR-486
targets FoxO1 and PTEN, the two components of the insulin/
IGF-1 signaling pathways that regulate muscle protein
metabolism.2,26 These experiments were undertaken because
we have demonstrated that CKD-induced muscle proteolysis
is activated by impaired insulin/IGF-1 signaling in the
muscles, and we have also found that suppression of PTEN
improves muscle growth and protein metabolism in the
muscles.27–29
What could explain the catabolic responses to FoxO1?
One possibility is that CKD increases glucocorticoid
production and impairs insulin/IGF-1/Akt/FoxO1 signaling
to stimulate Atrogin-1/MAFbx expression.22,30 Alternatively,
activated glucocorticoid receptors can interact with FoxO1 to
stimulate MuRF-1 expression in the muscles.24 In both cases,
the absence of FoxO1 would suppress the expression of both
Atrogin-1/MAFbx and MuRF-1. Another explanation for the
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in response to Dex were blocked by the miR-486mimic (*Po0.01 vs. CTL-miRþDex, n¼ 5). (b) The levels of p-Akt (ser 473) and phosphatase
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in PTEN content in myotubes transfected with miR-486 mimic. (d) The miR-486mimic stimulated the phosphorylation of FoxO1 and
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FoxO1-mediated stimulus is suggested by the report that
FoxO1 increases the expression of myostatin in the muscles.31
This is relevant because we and others have found that CKD
increases myostatin expression in the muscles, and hence the
absence of FoxO1 could reduce the catabolic influence of
myostatin.32,33 Finally, CKD and other catabolic conditions
can suppress MyoD to impair muscle cell growth and
differentiation.28,34 As deletion of FoxO1 in the muscles
reportedly increases MyoD,35,36 myogenesis might improve to
blunt CKD-induced muscle atrophy.
Inflammatory cytokines also stimulate muscle wasting via
increased expression of Atrogin-1/MAFbx and MuRF-1. For
example, tumor necrosis factor-a reportedly stimulates
Atrogin-1/MAFbx expression via FoxO4.13 We have found
that CKD increases circulating tumor necrosis factor-a,35 but
in the present experiments, we found no change in FoxO4
expression or phosphorylation. Consequently, we have
not identified a role for FoxO4 in muscle wasting stimulated
by CKD.
How might miR-486 influence CKD-stimulated muscle
wasting? Using real-time PCR analysis, we found that miR-486
is significantly decreased in the muscles of CKD mice
(Supplementary Figure S3A online), suggesting that the change
in miR-486 might contribute to CKD-induced catabolism.
Small et al.21 reported that miR-486 represses both PTEN and
FoxO1 and enhances PI3K/Akt signaling in cultured cardio-
myocytes. The link between their results and skeletal muscle
metabolism is that defects in IGF-1/PI3K/Akt signaling will
accelerate protein degradation.22,27 As miR-486 can inhibit
the translation of PTEN, there would be an increase in IGF/
PI3K/Akt signaling and a improvement in FoxO1 phosphor-
ylation. These responses would prevent FoxO1 translocation
into the nuclear, and hence would suppress skeletal muscle
proteolysis via the UPS. In fact, we found that introduction
of a long-lasting miR-486 mimic into primary cultures of muscle
cells significantly suppressed the expression of Atrogin-1/
MAFbx and MuRF-1 as well as Dex-stimulated muscle
protein degradation (Figure 3). In mice with CKD, the miR-
486 mimic inhibited both the expression of Atrogin-1/MAFbx
and MuRF-1 and the loss of muscle mass (Figure 7). It has
been reported that muscle-specific overexpression of miR-486
can impair muscle regeneration by interfering with cell cycle
kinetics of regenerating myofibers.37 In the present study,
enhancing of miR-486 in myofibers improved Akt signaling
and muscle protein metabolism in mice. Thus, miRNAs could
influence muscle metabolisms at different stage of muscle cell
development. We also found that enhanced miR-486 and Akt
signaling prevented atrophy of myotubes and muscle fibers,
the results consistent with a pathway by which enhancement
of miR-486 in muscle limits the protein wasting induced by
CKD and possibly other catabolic conditions. A potentially
negative response to overexpression of miR-486 would be
muscle hypertrophy as occurs in response to a constitutively
activated form of Akt or with myostatin deletion or with
exercise.35,38,39 However, we did not find hypertrophy in
primary cultures of myotubes or in normal muscles treated
with the miR-486 mimic. Similarly, the absence of FoxO1 did
not cause muscle hypertrophy in MFKO mice.
Why was the suppression of PTEN or FoxO1 incomplete?
Even though electroporation of miR-486 increased it 410-
fold above the endogenous level, FoxO1 or PTEN proteins
decreased only modestly (Figures 2 and 5). Possibly, the miR-
486 mimic did not create a sufficient amount of the RNA-
induced silencing complex that enables miR-486 to bind to
the 30-untranslated region of a mRNA.40 Regardless, a
miRNA can target several mRNAs without eliminating the
translation of targeted proteins and this could result in
incomplete suppression of PTEN and FoxO1. The ability of
the miRNA to influence more than one protein is important
because different proteins could influence activation of the
same pathway. For example, we found that miR-486
suppressed PTEN to improve insulin/IGF-1 signaling and
increase the phosphorylation of FoxO1. Augmenting this
activity was the miR-486-induced decrease in FoxO1 content,
and hence the expression of the Atrogin-1/MAFbx and
MuRF-1. By targeting PTEN and FoxO1, miR-486 acted to
prevent loss of muscle mass despite the presence of catabolic
stimuli.30
Our results suggest that pharmacological agents that target
FoxO1 might be developed into a method of preventing
muscle atrophy. For example, miR-486 (or other miRNAs)
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Figure 5 |Validation of microRNA (miRNA) electroporation
in vivo. (a–e) Tibialis anterior (TA) muscles were injected with
Dy547-labeled, control miRNA (cel-miR-67) and the efficiency of
transfection was assessed by measuring fluorescence. (a) TA
muscles injected with saline or (b) injected with Dy547-labeled,
control miRNA without electroporation. (c) At 2 days after
electroporation, Dy547-labeled miRNA was present in myofibers.
(d, e) The fluorescence was detected at 8 and 15 days after
electroporation. (f) The cel-miR-67 miRNA levels were examined
by real-time PCR.
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could inactivate FoxO1 protein to suppress muscle wasting.
Indeed, an orally active, small oligonucleotide delivery
method has been invented.41
MATERIALS AND METHODS
Mouse model of CKD
Mice were housed with a 12-h light/dark cycles and all animal
procedures were approved by the Baylor College of Medicine
Institutional Animal Care and Use Committee. MFKO mice were
obtained by crossing loxP-flanked FoxO1 mice (kindly provided by
Dr SY Chen, Baylor College of Medicine, Houston, TX) with MCK-
Cre mice (Jackson Lab, Bar Harbor, ME), and both strains are on
FVS background. Loxþ /þ plus Creþ mice were designated as
MFKO; loxþ /þ with Cre mice served as controls. CKD was
induced in 3-month-old MFKO or lox/lox control male mice by two-
stage nephrectomy under anesthesia.35 Briefly, the left kidney was
removed and 1 week later B70% of the right kidney was removed
and homeostasis was achieved by tissue adhesive (3M, St Paul, MN)
to prevent bleeding. After 1 week of 24% dietary protein, mice were
switched to a 40% protein diet (Harlan Teklab, Indianapolis, IN) for
at least 2 weeks. CKD was confirmed by serum creatinine
(Supplementary Figure S1A online) and blood urea nitrogen
(average 84±3.3 mg/dl in CKD groups). Serum creatinine level
was determined using Cayman’s creatinine kit (Cayman Chemical,
Ann Arbor, MI). Sham-operated, control mice underwent surgery
without damaging the kidneys and were fed the same diets.
Electroporation was accomplished by injecting 0.5 nmol of miRNA
in 20 ml phosphate-buffered saline into TA muscles. Electroporation
was performed at 80 V for 10 pulses (100 ms each pulse, 200 ms
intervals).22 The long-lasting miR-486 mimic and the control,
C. elegans miRNA (cel-miR-67) labeled with fluorescent Dy547,
were purchased from Dharmacon (Thermo Scientific, Chicago, IL).
At 14 days after electroporation, mice were anesthetized and TA
muscles as well as serum were collected for experiments or the
samples were frozen at 80 1C.
Protein synthesis and degradation
EDL or Sol muscles were maintained at resting length and incubated
in Krebs-Henseleit bicarbonate buffer with 10 mmol/l glucose as
described.42 Protein synthesis in EDL muscles was measured as the
rate of incorporation of L-[14C] phenylalanine, whereas protein
degradation was measured as the release of tyrosine. These amino
acids were used as neither is synthesized or degraded in the
muscle. For primary culture of myotubes, the rates of protein
synthesis were measured during a 16-h incubation with 3 mCi
L-[(3,5)-3H]-tyrosine (MP Biomedicals, Solon, OH). Subsequently,
myotubes were washed 3 with ice-cold phosphate-buffered saline
before adding 10% trichloroacetic acid to precipitate proteins. After
three additional phosphate-buffered saline washings, the pellets were
dissolved in 0.5 ml of 0.15 mol/l NaOH, and the incorporation of
radiolabeled tyrosine and protein content (Bio-Rad DC protein
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Figure 6 | Enhancing microRNA (miR)-486 protects against chronic kidney disease (CKD)-induced loss of skeletal muscle. (a) Tibialis
anterior (TA) muscles of sham-operated control, lox/lox (Sham), or CKD mice (FVB background) were transfected with control miRNA
(CTL-miR) or miR-486 mimic (miR-486mc). miR-486 mimic was detected by real-time PCR at 2 weeks after electroporation. (b) The
cross-sectional area of myofibers in TA muscles following electroporation with the miR-486 mimic or CTL-miR are shown. In situ
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assay kit; Bio-Rad, Hercules, CA) were measured. To measure
protein degradation, myotubes were prelabeled with L-[(3,5)-3H]-
tyrosine and incubated in Dulbecco’s modied Eagle’s medium
containing 2% horse serum. At different times, the trichloroacetic
acid–soluble radioactivity released from proteins was measured to
calculate the rate of protein degradation.42
Real-time quantitative PCR and northern blot
Total RNA was extracted using TRIzol (Sigma, St Louis, MO) and
precipitated in isopropanol overnight. cDNAs were synthesized
using MicroRNA cDNA kit (Exiqon, Woburn, MA). SYBR Green
Real-time quantitative PCR was performed with the CFX96 System
(Bio-Rad Laboratories). All miRNA expressions were normalized to
non-coding small nuclear RNA component of U6 (U6). The LNA
miRNA primers (miR-486, miR-1, miR-29a, miR-133, miR-206,
cel-miR-67, and U6) were purchased from Exiqon. Northern blot
analysis of Atrogin1/MAFbx and MuRF-1 was completed as
described.22
Histology and in situ hybridization
To assess differences in cross-sectional areas of myofibers, 5 mm
sections of TA muscles were stained with an anti-laminin antibody
(Sigma-Aldrich, St Louis, MO) or anti-FoxO1 (Cell Signaling,
Danvers, MA). The diameters of at least 300 myofibers per TA
muscle were assessed using Image J software (National Institutes of
Health, Frederick, MD). In situ hybridization was performed using a
digoxigenin-labeled miR-486, LNA probe (Exiqon) incubated at
42 1C overnight as described.43 After washing, the sections were
incubated with anti-digoxigenin antibody for 16 h and signals were
visualized with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl
phosphate (Roche Applied Science, Indianapolis, IN). A scrambled
control probe LNA (Exiqon) was used as a negative control.
Cell culture and western blot analyses
Satellites cells were isolated as described.20,28 Myoblasts were
maintained in F-10/Dulbecco’s modied Eagle’s medium with 10%
fetal bovine serum (HyClone, Logan, UT), penicillin (200 units/ml),
and streptomycin (50mg/ml; Invitrogen, Carlsbad, CA). Myotubes
were induced from myoblast by switching to Dulbecco’s modied
Eagle’s medium plus 2% horse serum (Sigma) for 72 h. miR-486
mimic (0.01 nmol/well in six-well dish) was transfected into
myotubes with Lipofectamine 2000 (Invitrogen); Control miRNA
(cel-miR-67) served as the control. After 36 h, rates of protein
synthesis and degradation were measured as described.42 For
western blotting, lysates of myotubes were prepared in RIPA buffer
(20 mmol/l Tris, pH 7.5, 5 mmol/l EDTA, 150 mmol/l NaCl, 1% NP-
40, 0.5% Na-deoxycholate, 0.025% SDS, 1 mmol/l Na-orthovana-
date, 10 mmol/l NaF, and 25 mmol/l b-glycerophosphate) containing
protease inhibitor (Roche). Skeletal muscle lysates were prepared
fromB50 mg muscle by homogenizing in 0.5 ml RIPA buffer. After
centrifugation at 15,000 g for 15 min at 4 1C, the supernatants
were subjected to western blotting as described.22
Statistical analysis
Results are presented as mean±s.e.m. Statistical analysis was
performed by analysis of variance followed by Tukey’s or Student–-
Newman–Keuls tests. Po0.05 was considered statistically significant.
Experiments were repeated at least three times.
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